Advertisement

Lessons Learned

  • David L. DeMets
  • Curt D. Furberg
  • Lawrence M. Friedman

Keywords

Case Study Approach Monitoring Committee Multiple Risk Factor Intervention Trial Cardiac Arrhythmia Suppression Trial Breast Cancer Prevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Canner PL. 1983. Monitoring of the data for evidence of adverse or beneficial treatment effects in the Coronary Drug Project. Control Clin Trials 4:467–483.CrossRefGoogle Scholar
  2. 2.
    DeMets D. 1984. Stopping guidelines vs. stopping rules: A practitioner’s point of view. Commun Statist-Theor Meth A 13:2395–2417.CrossRefGoogle Scholar
  3. 3.
    Fleming T, DeMets DL. 1993. Monitoring of clinical trials: issues and recommendations. Control Clin Trials 14:183–197.CrossRefGoogle Scholar
  4. 4.
    Pocock SJ. 1992. When to stop a clinical trial. BMJ 305:235–240.CrossRefGoogle Scholar
  5. 5.
    The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. 1994. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035.CrossRefGoogle Scholar
  6. 6.
    The World Medical Association. World Medical Association Declaration of Helsinki: Ethical principals for medical research involving human subjects. October 2000 amended version, with 2002 clarification. http://www.wma.net/e/policy/b3.htm.Google Scholar
  7. 7.
    Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. 1987. Publication bias and clinical trials. Control Clin Trials 8:343–353.CrossRefGoogle Scholar
  8. 8.
    Ioannidis JPA. 1998. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279:281–286.CrossRefGoogle Scholar
  9. 9.
    Thackray S, Witte K, Clark AL, Cleland JGF. 2000. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2:209–212.CrossRefGoogle Scholar
  10. 10.
    Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S for the 806 Investigator Team. 2000. Evaluation of HIV-1 Immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: a randomized controlled trial. JAMA 284:2193–2202.CrossRefGoogle Scholar
  11. 11.
    DeAngelis CD. 2000. Conflict of Interest and the Public Trust (editorial). JAMA 284:2237–2238.CrossRefGoogle Scholar
  12. 12.
    Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. 1993. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 111:761–772.CrossRefGoogle Scholar
  13. 13.
    Norton EWD. 1993. Letter to the editor. Arch Ophthalmol 111:1460.CrossRefGoogle Scholar
  14. 14.
    Marmor MF. 1993. Letter to the editor. Arch Ophthalmol 111:1460–1461.CrossRefGoogle Scholar
  15. 15.
    Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett C. 1993. Letter to the editor. Arch Ophthalmol 11:1463–1465.CrossRefGoogle Scholar
  16. 16.
    Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, et al. 1997. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 10:705–713.CrossRefGoogle Scholar
  17. 17.
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995–1003.CrossRefGoogle Scholar
  18. 18.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504.CrossRefGoogle Scholar
  19. 19.
    Chen YHJ, DeMets DL, Lan KKG. 2003. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Control Clin Trials 24:16–27.CrossRefGoogle Scholar
  20. 20.
    Writing Group for the Women’s Health Initiative Randomized Controlled Trial. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333.CrossRefGoogle Scholar
  21. 21.
    The Women’s Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. JAMA 291:1701–1712.CrossRefGoogle Scholar
  22. 22.
    Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D. 1996. Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women’s Health Initiative. Control Clin Trials 17:509–525.CrossRefGoogle Scholar
  23. 23.
    National Emphysema Treatment Trial Research Group. 2001. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 345:1075–1083.CrossRefGoogle Scholar
  24. 24.
    Lee SM, Wise R, Sternberg AL, Tonascia J, Piantadosi S, for the National Emphysema Treatment Trial Research Group. 2004. Methodologic isssues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. Clin Trials 1:326–338.CrossRefGoogle Scholar
  25. 25.
    National Emphysema Treatment Trial Research Group. 2003. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348:2059–2073.CrossRefGoogle Scholar
  26. 26.
    Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, et al. 1996. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335:1107–1114.CrossRefGoogle Scholar
  27. 27.
    Prentice RL. 1989. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431–440.CrossRefGoogle Scholar
  28. 28.
    Fleming TR, DeMets DL. 1996. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613.Google Scholar
  29. 29.
    Norwegian Multicenter Study Group. 1981. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807.CrossRefGoogle Scholar
  30. 30.
    CIBIS II Investigators and Committees. 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial. Lancet 353:9–13.CrossRefGoogle Scholar
  31. 31.
    The Multiple Risk Factor Intervention Trial Research Group. 1990. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. JAMA 263:1795–1801.CrossRefGoogle Scholar
  32. 32.
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57.CrossRefGoogle Scholar
  33. 33.
    Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. 2003. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073–2082.CrossRefGoogle Scholar
  34. 34.
    Psaty BM, Rennie D. 2003. Stopping medical research to save money. A broken pact with researchers and patients. JAMA 289:2128–2131.CrossRefGoogle Scholar
  35. 35.
    Boyd K. 2001. Commentary: Early discontinuation violates Helsinki principles. BMJ 322:605–606.Google Scholar
  36. 36.
    Food and Drug Administration, Department of Health and Human Services. 1998. International Conference on Harmonisation: Guidance on statistical principles for clinical trials; availability. Federal Register Vol 63, No 179:49583–98. http://www.fda.gov/cber/gdlns/ichclinical.pdf.Google Scholar
  37. 37.
    Armstrong PW, Newby LK, Granger CB, Lee KL, Simes J, Van de Werf F, White HD, Califf RM for the Virtual Coordinating Centre for Global Collaborative Cardiovascular Research (VIGOUR) Group. 2004. Lessons learned from a clinical trial. Circulation 110:3610–3614.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • David L. DeMets
    • 1
  • Curt D. Furberg
    • 2
  • Lawrence M. Friedman
    • 3
  1. 1.Department of Biostatistics and Medical InformaticsUniversity of WisconsinMadison
  2. 2.Department of Public Health SciencesWake Forest University School of MedicineWinston-Salem
  3. 3.Bethesda

Personalised recommendations